Author:
Fagiolino Pietro,Vázquez Marta
Publisher
Springer International Publishing
Reference30 articles.
1. Fagiolino P, Vázquez M, Olano I, Delfino A. Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. J Epilepsy Clin Neurophysiol. 2006;12:13–6. https://doi.org/10.1590/S1676-26492006000100004.
2. Fagiolino P, Vázquez M, Eiraldi R, Maldonado C, Scaramelli A. Efflux transporter influence on drug metabolism: theoretical approach for bioavailability and clearance prediction. Clin Pharmacokinet. 2011;50:75–80. https://doi.org/10.2165/11539230-000000000-00000.
3. Fagiolino P, Vázquez M, Orozco-Suárez S, Maldonado C, Alvariza S, Feria I, Ibarra M, Rocha L. Contribution of the antiepileptic drug administration regime in the development and/or establishment of pharmacoresistant epilepsy. In: Rocha L, Cavaleheiro EA, editors. Pharmacoresistance in epilepsy: from genes and molecules to promising therapies. New York/Heidelberg/Dordrecht/London: Springer Science + Business Media, LLC; 2013. p. 169–84. https://doi.org/10.1007/978-1-4614-6464-8_11.
4. Maldonado C, Fagiolino P, Vázquez M, Eiraldi R, Alvariza S, Bentancur C, Álvarez P. Time-dependent and concentration-dependent upregulation of carbamazepine efflux transporter. A preliminary assessment from salivary drug monitoring. Lat Am J Pharm. 2011;30:908–12. http://sedici.unlp.edu.ar/handle/10915/8235
5. Alvariza S, Fagiolino P, Vázquez M, Rosillo de La Torre A, Orozco-Suárez S, Rocha L. Verapamil effect on phenytoin pharmacokinetics in rats. Epilepsy Res. 2013;107:51–5. https://doi.org/10.1016/j.epilepsyres.2013.09.001.